Royalty Pharma Announces R&D Co-Funding Agreement With Johnson & Johnson For Total Of $500M In 2026 And 2027 To Advance Development Of JNJ-4804, Investigational Medicine For Autoimmune Diseases

Royalty Pharma plc has entered into a research and development co-funding agreement with Johnson & Johnson, committing a total of $500 million for the years 2026 and 2027. This funding will support the advancement of JNJ-4804, an investigational medicine targeting autoimmune diseases, which utilizes a novel co-antibody therapy to block IL-23 and TNF pathways.